In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: ColBenemid; Colchiquim; Colcrys; Colgout; Goutnil; Kolkicin; Konicine
- INDICATIONS: Gouty arthritis (in adults), gout, familial Mediterranean fever
- CLASS: Alkaloid, Anti-inflammatory, Covid-19 putative drug
- HALF-LIFE: 27–31 hours (following multiple doses)
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Aprepitant, Atazanavir, Atorvastatin, Azithromycin, Boceprevir, Clarithromycin, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Conivaptan, Cyanocobalamin, Cyclosporine, Darunavir, Dasatinib, Delavirdine, Digoxin, Diltiazem, Efavirenz, Erythromycin, Fenofibrate, Fibrates, Fluvastatin, Gemfibrozil, Grapefruit Juice, HMG-CoA reductase inhibitors, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Lopinavir, Ombitasvir/Paritaprevir/Ritonavir, P-glycoprotein inhibitors or inducers, Pravastatin, Protease inhibitors, Ritonavir, Rosuvastatin, Saxagliptin, Simvastatin, Strong CYP3A4 inhibitors, Telithromycin, Troleandomycin, Verapamil, Voriconazole
- See adverse reactions attributed to class:
Investigated for treating COVID-19.
Contra-indicated in patients with renal or hepatic impairment where P-glycoprotein or strong CYP3A4 inhibitors are also prescribed.
Low-dose colchicine (0.5 mg daily) has been approved by the FDA for secondary prevention in patients with coronary disease.
Please login to view the rest of this drug profile.
Page last updated 04/11/2024
